Exclusive Video Marketing Software for Startups 

Ensysce Biosciences Secures $60M in Funding

Ensysce Biosciences Inc., a San Diego, CA-based clinical phase company launching two new classes of novel opioids designed to treat severe pain, and eliminate opioid misuse, abuse and overdose, secured $60m in funding. GEM Global Yield LLC SCS will provide Ensysce with a share subscription facility of up to $60m for a 36-month term following the public listing of the company’s common stock. Ensysce will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. Concurrent with a public listing of its shares, the company will issue warrants to GEM to purchase outstanding common stock of the company. The company is led by Lynn Kirkpatrick, PhD, CEO, and Richard Wright, CBO, and Geoff Birkett, CCO.

Startup Around is now on Telegram and Whatsapp. For the best startup stories & resources, subscribe us on Telegram & Whatsapp.
World-class video marketing software for startups